Virios Therapeutics (NASDAQ:VIRI) Stock Price Down 7.3% - Should You Sell?

Key Points

• Virios Therapeutics (NASDAQ: VIRI) shares fell 7.3% on Tuesday to $2.78 (intraday low $2.77) on very light volume of 39,565 shares, about 96% below the average session volume.
• The stock trades below its 50‑day moving average ($2.99) and well under its 200‑day average ($4.66); the company has a market cap of roughly $53.5 million and a negative P/E of -10.30, reflecting small‑cap, loss‑making biotech risk.
• Virios is a clinical‑stage biopharmaceutical focused on anti‑fibrotic therapies, with lead candidate VTI‑1002 an oral small‑molecule inhibitor in trials for prevention and treatment of hypertrophic scars and keloids.

Virios Therapeutics, Inc. (NASDAQ:VIRI - Get Free Report)'s stock price fell 7.3% during trading on Tuesday . The stock traded as low as $2.77 and last traded at $2.78. 39,565 shares were traded during mid-day trading, a decline of 96% from the average session volume of 1,049,645 shares. The stock had previously closed at $3.00.

Virios Therapeutics Price Performance

The business's 50-day moving average price is $2.99 and its two-hundred day moving average price is $4.66. The company has a market capitalization of $53.54 million, a P/E ratio of -10.30 and a beta of 1.58.

Virios Therapeutics Company Profile

Virios Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for fibrotic diseases. The company leverages its proprietary small-molecule platform to identify and advance compounds designed to modulate key pathways involved in scar formation and tissue repair. By concentrating on conditions with high unmet medical need, Virios aims to improve patient outcomes through more effective and safer treatment options.

The company's lead development candidate, VTI-1002, is an oral small molecule inhibitor in clinical trials for the prevention and treatment of hypertrophic scars and keloids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.